ATE556071T1 - Kappa-opioidrezeptor-liganden - Google Patents

Kappa-opioidrezeptor-liganden

Info

Publication number: ATE556071T1
Authority: AT; Austria
Prior art keywords: kappa opioid; opioid receptor; receptor ligands; antagonists; kappa
Prior art date: 2005-02-17

Application number

AT06735365T

Other languages

English (en)

Inventor

Frank Ivy Carroll

Herman A Navarro

Lawrence E Brieaddy

Scott P Runyon

Thomas B James

Original Assignee

Res Triangle Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-17

Filing date

2006-02-17

Publication date

2012-05-15

2006-02-17 Application filed by Res Triangle Inst filed Critical Res Triangle Inst

2012-05-15 Application granted granted Critical

2012-05-15 Publication of ATE556071T1 publication Critical patent/ATE556071T1/de

Links

102000048260 kappa Opioid Receptors Human genes 0.000 title abstract 4
108020001588 κ-opioid receptors Proteins 0.000 title abstract 4
239000003446 ligand Substances 0.000 title 1
206010013663 drug dependence Diseases 0.000 abstract 2
208000022497 Cocaine-Related disease Diseases 0.000 abstract 1
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 abstract 1
208000003698 Heroin Dependence Diseases 0.000 abstract 1
229940123257 Opioid receptor antagonist Drugs 0.000 abstract 1
230000001668 ameliorated effect Effects 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
201000006145 cocaine dependence Diseases 0.000 abstract 1
229960002069 diamorphine Drugs 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000000159 protein binding assay Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)

AT06735365T 2005-02-17 2006-02-17 Kappa-opioidrezeptor-liganden ATE556071T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11/059,390 US7872023B2 (en)	2005-02-17	2005-02-17	Kappa opioid receptor ligands
PCT/US2006/005671 WO2006089130A1 (en)	2005-02-17	2006-02-17	Kappa opioid receptor ligands

Publications (1)

Publication Number	Publication Date
ATE556071T1 true ATE556071T1 (de)	2012-05-15

Family

ID=36816429

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06735365T ATE556071T1 (de)	2005-02-17	2006-02-17	Kappa-opioidrezeptor-liganden

Country Status (8)

Country	Link
US (3)	US7872023B2 (de)
EP (1)	EP1848275B1 (de)
JP (2)	JP5107728B2 (de)
AT (1)	ATE556071T1 (de)
AU (1)	AU2006214118B2 (de)
CA (1)	CA2598416C (de)
ES (1)	ES2383322T3 (de)
WO (1)	WO2006089130A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7189737B2 (en) *	1991-08-09	2007-03-13	Research Triangle Institute	Cocaine receptor binding ligands
US6538010B1 (en) *	2000-11-08	2003-03-25	Research Triangle Institute	Compounds and methods for promoting smoking cessation
US7872023B2 (en) *	2005-02-17	2011-01-18	Research Triangle Institute	Kappa opioid receptor ligands
US8048895B2 (en) *	2008-04-18	2011-11-01	Research Triangle Institute	Kappa opioid receptor ligands
EP2563124A4 (de) *	2010-01-19	2013-10-16	Res Triangle Inst	Kappa-opioid-rezeptor-bindende liganden
ES2533990T3 (es)	2010-02-24	2015-04-16	Research Triangle Institute	Antagonistas de receptores opioides de arilpiperazina
MD3344248T2 (ro)	2015-09-02	2022-10-31	Trevena Inc	Aza-heterociclic cu 6 elemente conținând compuși de modulare a receptorului delta-opioid, metode de utilizare și fabricare a acestora
KR102662065B1 (ko)	2017-02-17	2024-05-07	트레베나, 인코포레이티드.	7-원 아자-헤테로고리 함유 델타-오피오이드 수용체 조절 화합물, 및 그의 사용 및 제조 방법
WO2018152293A1 (en)	2017-02-17	2018-08-23	Trevena, Inc.	5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CN112569238A (zh) *	2019-09-30	2021-03-30	武汉大学	伊马替尼及其衍生物与镇痛药联合用药或复方制剂在治疗疼痛中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5319087A (en) *	1987-04-16	1994-06-07	Eli Lilly And Company	Piperidine opioid antagonists
US4891379A (en)	1987-04-16	1990-01-02	Kabushiki Kaisha Kobe Seikosho	Piperidine opioid antagonists
US4992450A (en) *	1987-04-16	1991-02-12	Eli Lilly And Company	Piperidine opioid antagonists
US5064834A (en) *	1987-04-16	1991-11-12	Eli Lilly And Company	Piperidine opioid antagonists
US6706880B2 (en)	1990-08-09	2004-03-16	Research Triangle Institute	Cocaine receptor binding ligands
US6123917A (en)	1990-08-09	2000-09-26	Research Triangle Institute	Method for making cocaine receptor binding ligands and intermediates therefor
US6329520B1 (en)	1990-08-09	2001-12-11	Research Triangle Institute	Cocaine receptor binding ligands
US5935953A (en)	1990-08-09	1999-08-10	Research Triangle Institute	Methods for controlling invertebrate pests using cocaine receptor binding ligands
US5128118A (en)	1990-08-09	1992-07-07	Research Triangle Institute	Cocaine receptor binding ligands
US5736123A (en)	1990-08-09	1998-04-07	Research Triangle Institute	Cocaine receptor binding ligands
US7189737B2 (en) *	1991-08-09	2007-03-13	Research Triangle Institute	Cocaine receptor binding ligands
US5496953A (en)	1990-08-09	1996-03-05	Research Triangle Institute	Cocaine receptor binding ligands
US7011813B2 (en)	1990-08-09	2006-03-14	Research Triangle Institute	Cocaine receptor binding ligands
US5380848A (en)	1990-08-09	1995-01-10	Research Triangle Institute	Cocaine receptor binding ligands
US6531483B1 (en)	1990-08-09	2003-03-11	Research Triangle Institute	Cocaine receptor binding ligands
US5141959A (en)	1990-09-21	1992-08-25	Bristol-Myers Squibb Company	Isoprenoid phospholipase a2 inhibitors and preparations comprising same
US5270328A (en) *	1991-03-29	1993-12-14	Eli Lilly And Company	Peripherally selective piperidine opioid antagonists
US5250542A (en) *	1991-03-29	1993-10-05	Eli Lilly And Company	Peripherally selective piperidine carboxylate opioid antagonists
US5159081A (en) *	1991-03-29	1992-10-27	Eli Lilly And Company	Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5298499A (en)	1991-07-05	1994-03-29	Research Triangle Institute	S-2-(substituted ethylamino)ethyl phosphorothioates
US5767131A (en) *	1993-04-05	1998-06-16	Synaptic Pharmaceutical Corporation	Dihydropyridines and new uses thereof
US5457208A (en) *	1993-06-21	1995-10-10	Regents Of The University Of Minnesota	Kappa opioid receptor antagonists
US6268369B1 (en) *	1994-11-16	2001-07-31	Synaptic Pharmaceutical Corporation	5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US5831095A (en)	1995-09-26	1998-11-03	Research Triangle Institute	Synthesis of 5-aminocarbonyl-5H-dibenzo a,d!cyclohepten-5,10-imine
US6159990A (en) *	1997-06-18	2000-12-12	Synaptic Pharmaceutical Corporation	Oxazolidinones as α1A receptor antagonists
US6358492B1 (en)	1997-10-07	2002-03-19	Research Triangle Institute	Dopamine transporter imaging ligand
US6900228B1 (en)	1998-03-10	2005-05-31	Research Triangle Institute	Opiate compounds, methods of making and methods of use
HN1999000149A (es) *	1998-09-09	2000-01-12	Pfizer Prod Inc	Derivados de 4,4-biarilpiperidina
US6218390B1 (en) *	1998-12-17	2001-04-17	Synaptic Pharmaceutical Corporation	Morpholinone and morpholine derivatives and uses thereof
GB9915616D0 (en)	1999-07-05	1999-09-01	Knoll Ag	Therapeutic agents
US6416735B1 (en)	1999-11-08	2002-07-09	Research Triangle Institute	Ligands for α-7 nicotinic acetylcholine receptors based on methyllcaconitine
US6479509B1 (en)	2000-05-22	2002-11-12	Research Triangle Institute	Method of promoting smoking cessation
US6538010B1 (en)	2000-11-08	2003-03-25	Research Triangle Institute	Compounds and methods for promoting smoking cessation
US6974824B2 (en)	2001-01-08	2005-12-13	Research Triangle Institute	Kappa opioid receptor ligands
WO2002055495A1 (en) *	2001-01-15	2002-07-18	Glaxo Group Limited	Aryl piperidine derivatives as inducers of ldl-receptor expression
US6559159B2 (en)	2001-02-01	2003-05-06	Research Triangle Institute	Kappa opioid receptor ligands
US7381721B2 (en)	2003-03-17	2008-06-03	Adolor Corporation	Substituted piperidine compounds
US7872023B2 (en) *	2005-02-17	2011-01-18	Research Triangle Institute	Kappa opioid receptor ligands
US7399762B2 (en) *	2005-04-25	2008-07-15	Research Triangle Institute	Opioid receptor agonist compounds and their use in treatment of pain
US7476679B2 (en) *	2005-07-26	2009-01-13	Research Triangle Institute	Octahydroisoquinoline compounds as opioid receptor modulators
US8048895B2 (en) *	2008-04-18	2011-11-01	Research Triangle Institute	Kappa opioid receptor ligands

2005
- 2005-02-17 US US11/059,390 patent/US7872023B2/en not_active Expired - Fee Related
2006
- 2006-02-17 AU AU2006214118A patent/AU2006214118B2/en not_active Ceased
- 2006-02-17 AT AT06735365T patent/ATE556071T1/de active
- 2006-02-17 EP EP06735365A patent/EP1848275B1/de not_active Expired - Lifetime
- 2006-02-17 CA CA2598416A patent/CA2598416C/en not_active Expired - Fee Related
- 2006-02-17 JP JP2007556327A patent/JP5107728B2/ja not_active Expired - Fee Related
- 2006-02-17 ES ES06735365T patent/ES2383322T3/es not_active Expired - Lifetime
- 2006-02-17 WO PCT/US2006/005671 patent/WO2006089130A1/en not_active Ceased
2010
- 2010-10-25 US US12/911,244 patent/US8173678B2/en not_active Expired - Fee Related
2012
- 2012-02-29 US US13/408,309 patent/US20120178781A1/en not_active Abandoned
- 2012-07-17 JP JP2012158446A patent/JP5571133B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7872023B2 (en)	2011-01-18
JP2012250983A (ja)	2012-12-20
JP5571133B2 (ja)	2014-08-13
ES2383322T3 (es)	2012-06-20
JP2008530238A (ja)	2008-08-07
WO2006089130A1 (en)	2006-08-24
CA2598416A1 (en)	2006-08-24
US20110065743A1 (en)	2011-03-17
EP1848275A1 (de)	2007-10-31
AU2006214118B2 (en)	2011-01-27
US8173678B2 (en)	2012-05-08
AU2006214118A1 (en)	2006-08-24
EP1848275B1 (de)	2012-05-02
EP1848275A4 (de)	2009-12-16
US20120178781A1 (en)	2012-07-12
US20060183743A1 (en)	2006-08-17
CA2598416C (en)	2014-05-20
JP5107728B2 (ja)	2012-12-26

Publication	Publication Date	Title
ATE389404T1 (de)	2008-04-15	Kappa-opioid-rezeptor-liganden
ATE442850T1 (de)	2009-10-15	Kappa-opioid-rezeptor-liganden
IL184733A0 (en)	2007-12-03	Human monoclonal antibodies to prostate specific membrane
CY2017039I2 (el)	2018-04-04	Αντισωματα υψηλης συγγενειας στον υποδοχεα της ανθρωπινης ιl-6
WO2007020502A3 (en)	2007-04-19	Cannabinoid receptor ligands and uses thereof
LTPA2017011I1 (lt)	2017-05-10	Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
IL191340A (en)	2015-08-31	Monoclonal antibodies against e8o
NL1033650A1 (nl)	2007-05-16	Antilichamen tegen myostatine.
CR20130418A (es)	2013-10-04	Anticuerpos contra la angiopoyetina 2 humana (divisional exp. 2011-0321)
WO2009002947A3 (en)	2009-04-02	Compounds and peptides that bind the trail receptor
WO2009149485A3 (en)	2010-06-10	Compounds for treating amyloidoses
WO2010004204A3 (fr)	2010-04-29	Antagonistes specifiques du recepteur fgf-r4
EA201000844A1 (ru)	2011-10-31	Связывающие wise агенты и эпитопы
MX2012006553A (es)	2012-08-03	Anticuerpos contra csf-1r humano y usos de los mismos.
NZ585465A (en)	2012-12-21	Monoclonal antibodies which bind to the extracellular domain of the axl receptor tyrosine kinase
EP2214676A4 (de)	2011-08-03	Substituierte diazepane als antagonisten an orexinrezeptoren
ATE509928T1 (de)	2011-06-15	8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
EP2131654A4 (de)	2011-02-02	Bipyridin-carboxamid-orexin-rezeptorantagonisten
ATE478069T1 (de)	2010-09-15	3,4-dihydro-2h-benzoä1,4üoxazin- und 3,4-dihydro- 2h-benzoä1,4üthiazin-verbindungen als alpha2c- adrenorezeptor-antagonisten
PL2238110T3 (pl)	2012-03-30	Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II
EP1983002A3 (de)	2009-03-11	Tyrosinphosphorylations-Stellen und spezifische Antikörper
ATE556071T1 (de)	2012-05-15	Kappa-opioidrezeptor-liganden
EA200701979A1 (ru)	2008-04-28	Способ получения опиоидных модуляторов
WO2008013934A3 (en)	2008-10-09	Tyrosine phosphorylation sites
IL205156A0 (en)	2010-11-30	(1,4-diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone ligands for nicotinic acetylcholine receptors, useful for the treatment of disease